Real-World Evidence Generation

About Amaros

Amaros is a private, early-stage company founded in 2021, focusing on applying AI and machine learning to ophthalmology data. Its core offering is the AmarosEngine™, a closed-system platform that unifies and analyzes real-world ophthalmic data to generate evidence-based insights. The company targets three primary customer segments: clinical practices (for operational efficiency and patient care), clinical trial sponsors/CROs (for study optimization and enrollment), and life sciences commercial teams (for market strategy). As a platform company, it appears to be in an early-revenue phase, building its network of provider clinics and technology partners.

About Natera

Natera's mission is to transform the management of cancer, pregnancy, and organ transplantation through advanced cell-free DNA analysis. The company has achieved a dominant position in minimal residual disease (MRD) testing with its Signatera™ assay, supported by over 400 peer-reviewed publications and a database of over 350,000 de-identified patient records. Its strategy centers on expanding its technology platform through acquisitions like Foresight Diagnostics, commercializing new tests like Zenith™ for rare disease, and leveraging its massive real-world data to accelerate biopharma partnerships and clinical adoption.

Therapeutic Areas